Axon Enterprise Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last twelve months. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axon Enterprise stock.
View analyst ratings for Axon Enterprise or view top-rated stocks.

Wall Street analysts have given Axon Enterprise a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Axon Enterprise wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Axon Enterprise saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,580,000 shares, an increase of 54.9% from the May 31st total of 1,020,000 shares. Based on an average trading volume of 405,500 shares, the short-interest ratio is currently 3.9 days. Approximately 2.5% of the company's shares are short sold.
View Axon Enterprise's Short Interest.

Axon Enterprise is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Axon Enterprise.

Axon Enterprise will be holding an earnings conference call on Thursday, August 5th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Axon Enterprise, Inc. (NASDAQ:AXON) issued its earnings results on Wednesday, May, 5th. The biotechnology company reported $0.31 EPS for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.10. The biotechnology company had revenue of $195.02 million for the quarter, compared to analyst estimates of $165.84 million. Axon Enterprise had a negative net margin of 7.37% and a negative trailing twelve-month return on equity of 6.05%. The business's quarterly revenue was up 32.5% on a year-over-year basis.
View Axon Enterprise's earnings history.

Axon Enterprise's stock was trading at $2.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXON stock has increased by 6,498.9% and is now trading at $186.09.
View which stocks have been most impacted by COVID-19.

Axon Enterprise updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $780 million-$820 million, compared to the consensus revenue estimate of $760.61 million.

6 analysts have issued 1 year target prices for Axon Enterprise's stock. Their forecasts range from $170.00 to $200.00. On average, they anticipate Axon Enterprise's share price to reach $186.80 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Axon Enterprise or view top-rated stocks among Wall Street analysts.

Some companies that are related to Axon Enterprise include Microsoft (MSFT), Oracle (ORCL), ServiceNow (NOW), VMware (VMW), Fortinet (FTNT), Proofpoint (PFPT), C3.ai (AI), Qualys (QLYS), Commvault Systems (CVLT), Progress Software (PRGS) and FalconStor Software (FALC).
View all of AXON's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXON stock can currently be purchased for approximately $186.09.

Axon Enterprise has a market capitalization of $12.04 billion and generates $681 million in revenue each year. The biotechnology company earns $-1,720,000.00 in net income (profit) each year or $0.11 on an earnings per share basis.

Axon Enterprise employs 2,548 workers across the globe.

The official website for Axon Enterprise is www.axovant.com.

Axon Enterprise is headquartered at 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS.

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at (480) 991-0797 or via email at [email protected]